School HPV Vaccine Reduces Cancer Risk for Unvaccinated Women

A recent study highlights the significant benefits of school-based immunisation against human papillomavirus (HPV), revealing that high vaccination rates can also protect unvaccinated women from developing pre-cancerous cervical cells. Conducted by researchers in Sweden, the findings advocate for robust universal vaccination initiatives targeting adolescents.

The study, published in The Lancet Public Health, analysed data from the Swedish national health registry, encompassing 857,168 women born between 1985 and 2000. Researchers divided participants into four categories based on their vaccination history: those who received opportunistic vaccinations, those involved in subsidised programmes, participants in catch-up programmes, and those who benefited from school-based vaccination initiatives.

HPV is primarily transmitted through skin contact during sexual activity. While most strains are harmless, approximately 13 high-risk types are responsible for nearly 99.7% of cervical cancers. In England, the HPV vaccine is administered to teenagers in Year 8, targeting those aged 12 to 13. The vaccine also provides protection against genital warts and head and neck cancers.

The research focused on rates of high-grade cervical lesions—severely abnormal cells that can result from chronic HPV infection and may lead to cancer if untreated. The findings indicated that unvaccinated women exposed to school-based vaccination exhibited a significantly lower incidence of these lesions compared to their counterparts in the opportunistic vaccination group. Women born between 1999 and 2000 who did not receive the vaccine in school had roughly half the risk of developing serious pre-cancerous changes compared to those born between 1985 and 1988.

Implications for Public Health Policy

The researchers concluded, “When combined with existing evidence, our findings support that high HPV vaccination coverage substantially reduces the incidence of high-grade cervical lesions in both the vaccinated population, through direct protection, and the unvaccinated population, through herd effects.” They emphasised the importance of expanding school-based vaccination programmes as a cost-effective public health strategy to lower the risk of cervical cancer across entire populations.

These results resonate with current public health goals. The NHS aims to increase HPV vaccine uptake among girls to 90% as part of a broader initiative to eliminate cervical cancer by 2040. Recent data released in July shows a vaccination rate of 76.7% among girls and 71.2%% among boys aged 14 to 15 in Year 10. Additionally, the uptake in Year 8 has risen to 72.9%% for girls and 67.7%% for boys, a noticeable increase from 71.3%% and 65.2%% respectively a year prior.

In light of this study, it is clear that the benefits of HPV vaccination extend beyond those who are immunised, underscoring the critical need for continued public health efforts in vaccination initiatives targeting school-aged populations.